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Although Ras and Raf cause transformation of NIH
3T3 fibroblasts, only Ras causes transformation of RIE-1
intestinal epithelial cells. To determine if the inability of
Raf to transform RIE-1 cells is due to a failure to dereg-
ulate cell cycle progression, we evaluated the conse-
quences of sustained Ras and Raf activation on steady
state levels of cyclin D1, p21CIP/WAF, and p27KIP1. Both
Ras- and Raf-transformed NIH 3T3 cells showed up-reg-
ulated expression of cyclin D1, p21, and p27 protein,
increased retinoblastoma (Rb) hyperphosphorylation,
and increased activation of E2F-mediated transcription.
Similarly, Ras-transformed RIE-1 cells also showed up-
regulation of cyclin D1, p21, and hyperphosphorylated
Rb. In contrast, Ras-mediated down-regulation of p27
was seen in RIE-1 cells. Conversely, stable expression of
activated Raf alone caused only a partial up-regulation
of p21 and Rb hyperphosphorylation but no activation
of E2F-responsive transcription or down-regulation of
p27 in RIE-1 cells. Moreover, we found that the AP-1 site
was dispensable for Ras-mediated stimulation of the cy-
clin-D1 promoter in NIH 3T3 cells but was essential for
Ras-mediated stimulation in RIE-1 cells. Thus, up-regu-
lation of p21, rather than the down-regulation seen in
previous transient expression studies, is seen with sus-
tained Ras activation. Additionally, p27 may serve a pos-
itive (NIH 3T3) or negative (RIE-1) regulatory role in
Ras transformation that is cell type-dependent. The in-
volvement of Raf and phosphatidylinositol 3-kinase in
mediating Ras changes in cyclin D1, p21, and p27 was
also very distinct in NIH 3T3 and RIE-1 cells. Taken
together, these results demonstrate the importance of
Raf-independent pathways in mediating oncogenic Ras
deregulation of cell cycle progression in epithelial cells.
Mutated and constitutively activated forms of Ras are found
in 30% of human cancers (1, 2). Therefore, the signaling path-
ways that mediate oncogenic Ras growth transformation have
been studied intensively. Although it is clear that Ras activa-
tion of the Raf/MEK1/ERK mitogen-activated protein kinase
cascade is important for Ras transformation, it has also become
clear that Ras transformation also requires the activation of
multiple Raf-independent effector pathways (3). Furthermore,
the pathways important for Ras transformation also exhibit
cell type differences.
In addition to Raf, Ras also associates with a spectrum of
other downstream effector targets. Among these, the phosphoi-
nositide 3-phosphate lipid kinases (PI3Ks) represent the sec-
ond best characterized effectors of Ras (4). Activated PI3K, a
lipid kinase, facilitates the conversion of phosphatidylinositol
4,5-phosphate to phosphatidylinositol 3,4,5-phosphate. Phos-
phatidylinositol 3,4,5-phosphate levels are elevated in Ras-
transformed cells and promote the activation of the Akt/protein
kinase B serine/threonine kinase (5, 6). A third class of Ras
effectors is a family of guanine nucleotide exchange factors
(RalGDS, RGL, and Rlf/RGL2) that serve as activators of the
Ral small GTPases (7, 8). The contribution of PI3K and Ral-
GDS to Ras transformation has been supported by studies with
effector domain mutants (E37G and Y40C) of activated Ha-
RasVal-12 that cause the loss of Raf binding and consequently a
failure to activate ERKs (6, 9–11). RasVal-12/Gly-37 is also im-
paired in interaction with PI3K but retains interaction with
RalGDS, whereas the RasVal-12/Cys-40 mutant is impaired in
interaction with RalGDS but retains interaction with PI3K.
The ability of both mutants to cause growth transformation of
NIH 3T3 cells demonstrates that Ras can also cause transfor-
mation by Raf-independent pathways.
One aspect of Ras signaling clearly important for growth
transformation involves regulation of components of the cell
cycle machinery that is critical for progression through the G1
phase (12–14). A significant component of Ras regulation of cell
cycle progression involves Ras stimulation of events that lead
to the hyperphosphorylation and inactivation of the Rb tumor
suppressor protein (15). Rb hyperphosphorylation then results
in the release of bound E2F transcription factors, thus allowing
E2F to stimulate the transcription of genes whose products
promote G1 progression (16). Although how Ras causes inacti-
vation of the Rb pathway has been studied extensively, a clear
understanding of this process remains to be determined.
The prevailing evidence implicates Ras regulation of both
positive (cyclin D1) and negative (p21CIP1/WAF1 and p27KIP1)
factors in causing Rb inactivation to promote G1 progression.
However, which Ras effector pathway regulates these cell cycle
components and how their functions are then altered are not
clearly understood. The lack of a coherent picture of Ras and
cell cycle regulation is due, in part, to differences in experimen-
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tal analyses (transient versus stable Ras activation) and to cell
type differences (fibroblasts versus epithelial cells) in how Ras
functions. Additionally, although p21 and p27 can act as inhib-
itors of cyclin D-CDK complexes, they may also serve a positive
role in G1 progression by promoting cyclin D-CDK assembly
and nuclear localization. Much of our knowledge has come from
the study of fibroblast models. Thus, whether the links between
Ras and the cell cycle in epithelial cells, the cell type from
which the majority of ras mutation positive cancers arise, will
show cell type differences is not clear.
The best characterized cell cycle target of Ras is cyclin D1.
Cyclin D1, a major positive regulator of cell cycle progression,
is up-regulated in response to both transient and sustained Ras
activation in a variety of cell types (17–22). Increased cyclin D1
facilitates increased formation of active cyclin D1-cyclin-de-
pendent kinase (CDK4 and CDK6) complexes that phosphoryl-
ate and inactivate Rb function. Ras up-regulation of cyclin D1
protein expression is mediated, in large part, by stimulation of
transcription from the cyclin D1 promoter (19). To date, this
up-regulation has been attributed mainly to Ras activation of
the Raf/ERK pathway. However, a contribution of PI3K and
RalGDS effector pathways has also been shown (23, 24).
The second most studied link between Ras and cell cycle
regulation involves the regulation of expression of the p21CIP1
CDK inhibitor. The levels of p21 are low during quiescence and
tend to increase in response to mitogenic stimuli, particularly
those that activate the Raf/MEK/ERK pathway (25, 26). How-
ever, the majority of observations suggest that p21 antagonizes
Ras growth stimulation. Transient activation of low levels of
Ras or Raf in NIH 3T3 cells did not induce p21 expression and
caused a mitogenic response (27, 28). In contrast, high Ras or
Raf induction caused an up-regulation of p21 and was growth
inhibitory. Similarly, it was observed that microinjection of
activated Ras alone into Swiss 3T3 mouse fibroblasts induced
p21 and did not stimulate proliferation, whereas co-expression
of activated RhoA prevented p21 induction and thereby allowed
Ras to induce a proliferative response (29). Consistent with a
role for p21 in antagonizing Ras function, loss of p21 but not
p27 function in primary mouse keratinocytes caused increased
susceptibility to transformation by oncogenic Ras (30). Finally,
ectopic expression of p21 inhibited Ras transformation of NIH
3T3 cells (31). Thus, it is currently believed that oncogenic Ras
down-regulation of p21 expression, via the Raf/ERK pathway,
is required for Ras to cause growth transformation.
A link between Ras and a second CDK inhibitor p27KIP1,
where Ras causes down-regulation of p27 expression via the
Raf/ERK pathway, has also been observed in a variety of cell
types. p27 protein levels are regulated post-translationally and
exhibit a pattern of expression that is opposite that of p21. p27
levels are elevated in quiescent cells and down-regulated in
response to mitogenic stimuli via a Ras-dependent mechanism
(32, 33). Microinjection of activated Ras caused transient down-
regulation of p27 in Swiss 3T3 cells (29). Transient activation of
Raf-1 or MEK1 activation caused down-regulation of p27 pro-
tein levels in NIH 3T3 cells (21, 34). Sustained expression of
oncogenic Ras caused a down-regulation of p27 protein levels in
CCL39 fibroblasts and IEC-6 intestinal epithelial cells that
was dependent on the Raf/ERK pathway (35, 36). In contrast to
these studies, p27 levels were unchanged in Ras-transformed
NIH 3T3 cells (37), and induction of activated MEK did not
cause down-regulation of p27 in NIH 3T3 cells (38). Thus,
whether a down-regulation of p27 is required for Ras transfor-
mation and how Ras might regulate p27 expression are issues
that are currently not clearly understood.
Previously, we reported that the Raf/ERK cascade alone,
although necessary, was not sufficient for Ras to cause trans-
formation of RIE-1 rat intestinal epithelial cells (39). Based on
the importance of the Raf/ERK pathway in the deregulation of
cell cycle components in rodent fibroblasts, the failure of Raf to
cause transformation of RIE-1 cells suggests that activation of
the Raf/ERK pathway alone may not be sufficient to inactivate
the Rb pathway in RIE-1 cells. Alternatively, both Ras and Raf
may cause Rb inactivation, but this alone is not sufficient, and
Ras causes additional changes required to deregulate cell cycle
progression. In the present study, we evaluated whether the
contribution of the Raf/ERK pathway to Ras deregulation of
cell cycle progression differs in NIH 3T3 fibroblasts and RIE-1
epithelial cells. Our results demonstrate cell type differences in
Ras regulation of cell cycle progression and the importance of
Raf-independent signaling pathways in Ras transformation of
epithelial cells.
EXPERIMENTAL PROCEDURES
Molecular Constructs and Reagents—-Mammalian expression vec-
tors containing cDNA sequences encoding constitutively activated mu-
tants of Ras (Ha-RasLeu-61, K-Ras4BVal-12, and N-RasAsp-12) or Raf-1 (the
NH2-terminal truncated and constitutively 22W mutant or the consti-
tutively membrane-targeted Raf-CAAX mutant) were generated using
pZIP-NeoSV(x)1 retrovirus vector with a neomycin resistance marker
where expression of the inserted gene is regulated from the Moloney
retrovirus long terminal repeat promoter and have been described
previously (39–43). pCGN-hygro mammalian expression vectors encod-
ing the highly transforming Raf-CAAX and Ha-RasLeu-61 proteins were
generated by subcloning each cDNA sequence into pCGN in frame with
an NH2-terminal hemagglutinin epitope tag where expression is under
the control of the cytomegalovirus (CMV) promoter (39). The pBSTR1
mammalian expression vector encoding human cyclin D1 cDNA expres-
sion vector, as described previously (44), is under the control of a
tetracycline-repressible CMV promoter and also contains a puromycin-
selectable marker. Western blot analyses to verify expression were done
using monoclonal antibodies against cyclin D1 (17–32G-11 and HD-11;
Santa Cruz Biotechnology), polyclonal antibodies against an amino-
terminal peptide of rat cyclin E (sc-481; Santa Cruz Biotechnology),
rabbit polyclonal anti-Raf-1 (C-12; Santa Cruz Biotechnology), mono-
clonal or rabbit polyclonal antibodies against p21WAF (Ab4/5; Upstate
Biotechnology, Inc.), and anti-Rb monoclonal antibody (14001A;
PharMingen) which detects both active hypophosphorylated Rb and
inactive hyperphosphorylated Rb.
Cell Culture and Transformation Assays—RIE-1 rat intestinal epi-
thelial cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% fetal bovine serum. NIH 3T3 cells were
maintained in DMEM supplemented with 10% calf serum. The intro-
duction of plasmid DNA constructs into NIH 3T3 cells was done by
calcium phosphate precipitation (45), whereas RIE-1 cells were trans-
fected using Superfect (Qiagen) according to the manufacturer’s sug-
gestions. To establish cell lines of NIH 3T3 or RIE-1 cells stably ex-
pressing activated Ras (Ha-RasLeu-61, N-RasAsp-12, or K-Ras4BVal-12) or
Raf-22W, transfected cultures were maintained in growth medium sup-
plemented with 400 mg per ml of G418 (Geneticin; Life Technologies,
Inc.), and multiple G418-resistant colonies (.50) were pooled together
and used for analyses. Some analyses were also performed on RIE-1
cells stably infected with pZIP-NeoSV(x)1 retrovirus vector constructs
expressing activated Ha-RasLeu-61, K-RasVal-12,, N-RasAsp-12, or Raf-
22W. The resulting cell lines were designated NIH(Ras) and NIH(Raf)
or RIE(Ras) and RIE(Raf). The U0126 MEK1/2 (provided by J. Trzas-
kos; DuPont) and LY294002 PI3K (Sigma) inhibitors were dissolved in
dimethyl sulfoxide (Me2SO), and control cultures were treated with the
equivalent final concentrations of Me2SO (vehicle).
To determine if cyclin D1 overexpression, either alone or in cooper-
ation with Raf-22W, could transform RIE-1 cells, co-transfection focus-
formation assays were performed. Cells were co-transfected with 0.5 mg
of empty pZIP-NeoSV(x)1, pZIP-K-ras(12V), or pZIP-raf-22W, either
alone or together with 0.5 mg of pCMV-cyclin D1. The appearance of
transformed foci was quantitated after 21 days.
Western Blot Analyses of Protein Expression—Asynchronous, expo-
nentially growing subconfluent cultures of cells were harvested with
lysis buffer containing 0.5% Nonidet P-40, 50 mM Tris, pH 7.5, 150 mM
NaCl, 50 mM NaF, 1 mM Na3VO4, 1 mM dithiothreitol, 1 mM phenyl-
methylsulfonyl fluoride, 25 mg/ml aprotinin, and 25 mg/ml leupeptin.
Protein concentrations were determined using BCA protein assay kit
(Pierce). After separation by SDS polyacrylamide gel electrophoresis
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(SDS-PAGE), the resolved proteins were transferred to polyvinylidene
difluoride membranes. Membranes were blocked for 1 h in 5% nonfat
dry milk, probed with the appropriate antibody for 1–2 h at room
temperature or overnight at 4 °C, washed, probed with the appropriate
secondary antibody (Amersham Pharmacia Biotech) for 1 h, washed,
and exposed to x-ray film.
Transient Expression Reporter Assays—For transient expression re-
porter assays, parental RIE-1 cells were transfected with Superfect or
Effectene (Qiagen) as suggested by the manufacturer’s protocols.
Briefly, RIE-1 cells were seeded the day before transfection and trans-
fected with cationic lipids for 24 h. The growth medium was then
replaced with DMEM supplemented with 0.2% fetal bovine serum. Cells
were serum-starved for 24 h and harvested with 300 ml of luciferase
lysis buffer (PharMingen), and 50 ml of lysate was analyzed by using
enhanced chemiluminescence reagents and a Monolight 2010 luminom-
eter (Analytical Luminescence). To normalize fold activation of the
reporter construct to protein levels, protein concentrations were deter-
mined by BCA protein assay (Pierce). The cyclin D1-luciferase construct
consists of 963 base pairs of wild type sequences or sequences with point
mutation altering the AP1 site of the human cyclin D1 promoter con-
trolling the expression of the luciferase gene (19). The E2F-1-responsive
luciferase promoter was provided by P. Farnham and has been de-
scribed previously (46)
Immunoprecipitation and Kinase Assays—Cyclin D1-associated ki-
nase or CDK4 assays were performed as described previously (47).
Briefly, RIE-1 cells stably expressing the indicated DNAs were seeded
1–2 days before harvesting. Cyclin D1 or CDK4 were immunoprecipi-
tated (17–32G and anti-mouse CDK4, gift from Y. Xiong, University of
North Carolina, Chapel Hill), and the activity of the complex was
determined using 0.5–2 mg of GST-Rb substrate. Reactions were
stopped with 23 Laemmli sample buffer and were subjected to SDS-
PAGE. The gel was then stained with Coomassie Blue to visualize
protein substrates, destained, and subsequently dried for 1 h. Hyper-
film (Amersham Pharmacia Biotech) or a PhosphorImager screen was
exposed for an appropriate amount of time, with radioactivity then
measured using a PhosphorImager (Molecular Dynamics). For immu-
noblotting, cells were harvested as described above, and equal protein
was subjected to SDS-PAGE. Cyclin E-associated kinase assays were
performed as described previous (47). Briefly, cyclin E was immunopre-
cipitated (sc-481; Santa Cruz Biotechnology), and the activity of the
complex was determined using 2 mg of histone H1 as substrate.
RESULTS
Oncogenic Ras Utilizes Raf-independent Pathways to Cause
Up-regulation of Cyclin D1 in RIE-1 Epithelial Cells—It is well
documented that oncogenic Ras causes up-regulation of cyclin
D1, in large part, by activation of the Raf/MEK/ERK pathway
(12–14). Considering these observations, we sought to deter-
mine the importance of Raf-dependent and Raf-independent
pathways in the up-regulation of cyclin D1 in RIE-1 epithelial
cells. Since we demonstrated previously that Ras, but not Raf,
could transform RIE-1 epithelial cells (39), we postulated that
the failure of activated Raf to transform RIE-1 cells may be due
to its inability to deregulate cyclin D1 or other key components
of the cell cycle machinery.
First, we compared the consequences of sustained Ras or Raf
activation on cyclin D1 expression in NIH 3T3 and RIE-1 cells.
Consistent with previous studies, we observed that NIH 3T3
cells stably expressing activated and transforming mutants of
Raf-1 or Ras (designated NIH(Raf) or NIH(Ras), respectively)
showed elevated steady state levels of cyclin D1 protein (Fig.
1A). In contrast, only RIE-1 cells stably expressing activated
Ras (RIE(Ras)), and not Raf (RIE(Raf)), showed up-regulated
levels of cyclin D1 protein when assayed in either exponentially
growing or confluent cultures. Since RIE(Raf) cells are morpho-
logically indistinguishable from those expressing the empty
vector, we verified that the activated Raf-22W protein was
stably expressed in RIE(Raf) cells and that it caused stable
up-regulation of ERK activity (Fig. 6C). These observations
show that activation of a Raf-independent pathway(s) is re-
quired for Ras to cause cyclin D1 up-regulation in RIE-1 epi-
thelial cells.
Next, we determined whether this increase in cyclin D1
protein levels corresponded to differences in the ability of Raf
and Ras to stimulate transcription from the cyclin D1 pro-
moter. For these analyses, transient expression analyses were
performed on parental RIE-1 cells transiently transfected with
expression plasmids encoding two different activated versions
of Raf-1 (Raf-22W or Raf-CAAX) or Ras (Ha-RasLeu-61 or K-
RasVal-12) together with a reporter plasmid where the lucifer-
ase gene is under the control of the human cyclin D1 promoter.
When analyzed in NIH 3T3 cells, we observed that both acti-
vated Raf and Ras caused comparable activation of the pro-
moter (data not shown). However, Ras but not Raf, stimulated
cyclin D1 transcription when assayed in RIE-1 cells (Fig. 2).
Additionally, Northern blot analyses determined that the
steady state levels of endogenous cyclin D1 mRNA were ele-
vated in RIE(Ras) but not RIE(Raf) cells (data not shown).
These results suggest that the Ras-mediated increase in cyclin
D1 protein is due, in part, to increased transcription from the
cyclin D1 promoter via stimulation of Raf-independent
pathways.
Oncogenic Ras Causes Increases in Cyclin D1-associated Ki-
nase Activity and Rb Hyperphosphorylation—Next, we deter-
mined if the elevated levels of cyclin D1 protein observed in
Ras-transformed RIE-1 cells corresponded to increased cyclin
D1-associated kinase activity. In vitro kinase assays were per-
formed on immunoprecipitated cyclin D1 and showed that
there was an increase in cyclin D1-associated kinase activity in
RIE(Ras) but not RIE(Raf) cells (Fig. 3A). We also determined
FIG. 1. Ras, but not Raf, up-regu-
lates steady state cyclin D1 protein
levels. A, equal numbers of RIE-1 cells
stably transfected with pZIP-NeoSV(x)1
empty vector or encoding Raf-22W, Ha-
RasLeu-61, or K-RasVal-12 were plated and
cultured 1–2 days before harvesting for
analyses. Exponentially growing and con-
fluent cells were harvested, and total pro-
tein concentrations were determined by
BCA protein assay. The relative levels of
cyclin D1 protein expression were deter-
mined by a Western blot of equal total
cellular lysates using an anti-cyclin D1
antiserum. Lysates from both NIH 3T3
and RIE-1 stably expressing the indicated
constructs were analyzed for comparison.
B, protein expression of Raf-22W was an-
alyzed in both NIH 3T3 and RIE-1 cells as
stated in A.
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that cyclin E-associated kinase activity (Fig. 3B), as well as
CDK4 activity (due to cyclin D1 and D2 association; Fig. 3C)
were elevated in RIE(Ras) but not RIE(Raf) cells. Thus, Ras
activation of CDK activity important for G1 progression was
critically dependent on activation of Raf-independent
signaling.
We then determined if this corresponded to an increased
hyperphosphorylation and inactivation of Rb. By using an an-
tibody that recognizes both hypo- and hyperphosphorylated Rb,
Western blot analyses showed that both NIH(Ras) and NI-
H(Raf) cells showed elevated levels of hyperphosphorylated Rb
protein. Although RIE(Raf) cells showed elevated Rb hyper-
phosphorylation over empty vector transfected cells, it was
lower than that observed for Rb in RIE(Ras) cells (Fig. 4A).
This suggested that Raf may cause a partial inhibition of Rb
function and, consequently, lead to activation of E2F-mediated
transcription. To address this possibility, we evaluated the
ability of Raf and Ras to activate E2F-responsive gene expres-
sion. Whereas both Ras and Raf caused activation of transcrip-
tion from an E2F-responsive reporter plasmid when assayed in
NIH 3T3 cells, only Ras activated transcription when assayed
in RIE-1 cells (Fig. 4B). Thus, the limited ability of Raf to cause
Rb hyperphosphorylation in RIE-1 cells was not sufficient to
lead to activation of E2F-mediated transcription.
The inability to cause up-regulation of cyclin D1 may con-
tribute to the inability of Raf to cause transformation of RIE-1
cells. To address this possibility we forced overexpression of
cyclin D1, together with activated Raf-22W, to determine if this
could cause transformation of RIE-1 cells. Two approaches
were employed to accomplish this. First, we performed focus
formation assays in RIE-1 cells to determine whether co-ex-
pression of exogenous cyclin D1 together with Raf-22W was
sufficient to cause focus formation in RIE-1 cells. We found that
forced expression of cyclin D1 alone or together with activated
Raf-22W did not result in focus-forming activity in transfected
RIE-1 cells (Fig. 5A). Second, we established RIE-1 cells that
stably overexpressed both cyclin D1 and Raf-22W to determine
if cyclin D1 and Raf-22W overexpression could cooperate and
cause morphologic transformation. Western blot analyses of
the resulting cells confirmed the expression of activated Raf
and the overexpression of cyclin D1 at levels comparable to that
seen in RIE(Ras) cells (Fig. 5B). However, simultaneous ex-
pression of both cyclin D1 and Raf was not sufficient to cause
morphologic or growth transformation of RIE-1 cells. We con-
clude that the inability of Raf to up-regulate cyclin D1 alone
does not account for its inability to cause transformation of
RIE-1 cells.
Both Raf and PI3K Effector Pathways Are Important for
Cyclin D1 Up-regulation—In contrast to NIH 3T3 cells, our
analyses showed that Ras up-regulation of cyclin D1 is depend-
ent on the activity of Raf-independent pathways. To evaluate
the nature of these pathways, we employed three experimental
approaches. First, we utilized pharmacologic inhibitors of MEK
and PI3K to assess the importance of the Raf and PI3K effector
pathways in causing up-regulation of cyclin D1. Strikingly, we
found that the treatment of RIE(Ras) cells with the MEK
inhibitor (U01026), but not the PI3K inhibitor (LY294002),
caused a reversion of the transformed morphology of RIE(Ras)
cells (Fig. 6A). However, treatment with either U01026 or
FIG. 2. Ras, but not Raf, up-regu-
lates transcription from the cyclin
D1 promoter. RIE-1 cells were tran-
siently co-transfected with the cyclin D1-
Luciferase reporter plasmid, together
with either the empty pCGN-hygro ex-
pression vector (A) or pCGN-hygro encod-
ing activated Raf-CAAX or Ha-RasLeu-61,
or the empty pZIP-Neo(x)1 expression
vector or pZIP-NeoSV(x)1 encoding acti-
vated Raf-22W or K-RasVal-12 (B). DNA
was transfected via incubation with cati-
onic lipids for 24 h followed by incubation
in complete medium for 24 h and a sub-
sequent starvation for 12–16 h. Fold lu-
ciferase activity was normalized by total
protein analyzed.
FIG. 3. Ras utilizes Raf-independent pathways to up-regulate
cyclin-associated kinase activity in RIE-1 cells. A, exponentially
growing cells stably expressing each DNA were harvested, and cyclin
D1-associated kinase assays were performed. Cyclin D1 was immuno-
precipitated, and phosphorylation of recombinant GST-Rb fusion pro-
tein was measured by an in vitro kinase assay, and phosphorylation
was quantitated using PhosphorImager analyses. B, Ras utilizes Raf-
independent pathways to up-regulate cyclin E-associated kinase activ-
ity. Exponentially growing RIE-1 cells stably expressing the indicated
protein were harvested, and cyclin E-associated kinase activity was
determined by immunoprecipitation (IP) of cyclin E, and phosphoryla-
tion of histone H1 was determined in an in vitro kinase assay. Recom-
binant Sf9 insect cell-expressed cyclin-E/CDK2 was assayed in parallel
as an internal control for the in vitro kinase assay. Ras utilizes Raf-
independent pathways to up-regulate cyclin E-associated kinase activ-
ity. C, Ras, but not Raf, activation causes an increase in CDK4 kinase
activity. Exponentially growing RIE-1 cells stably expressing the indi-
cated protein were harvested, and CDK4 was immunoprecipitated, and
phosphorylation of recombinant GST-Rb fusion protein was determined
in an in vitro assay. Data shown are representative of at least three
independent experiments.
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LY294002 inhibitor treatment caused a reduction in cyclin D1
protein expression to levels that were less than, or similar to,
the low level seen in untransformed RIE-1 cells (Fig. 6B).
Moreover, measurement of phospho-ERK levels indicated that
the reduction in cyclin D1 levels associated with the inhibition
of PI3K was not due to nonspecific LY294002 inhibition of ERK
activation (Fig. 6C). These results suggest that both Raf and
PI3K effector pathways are important for up-regulation of cy-
clin D1 in RIE-1 cells by oncogenic Ras and are consistent with
recent studies implicating PI3K in stimulation of cyclin D1
levels in rodent fibroblasts (23, 24, 48). Additionally, since
LY294002 treatment reduced cyclin D1 levels and reduced
rates of proliferation (data not shown), but did not cause a
reversion of morphologic transformation, up-regulation of cy-
clin D1 appears to be required to maintain only some, but not
all, aspects of the transformed state. This observation is con-
sistent with studies with Ras-transformed IEC-18 rat intesti-
nal epithelial cells, where antisense down-regulation of cyclin
D1 did cause a reduction in cell proliferation (17).
We next utilized effector domain mutants of Ha-RasVal-12 to
assess the contribution of the Raf and PI3K effector pathways
to Ras up-regulation of cyclin D1 expression (6, 9–11). The
Ha-RasVal-12/Ser-35 effector domain mutant retains the ability to
interact with Raf, but not PI3K or RalGDS. The Ha-RasVal-12/
Cys-40 effector domain mutant retains the ability to interact
with PI3K but not Raf or RalGDS. We showed previously that
both effector domain mutants could cause limited growth
transformation of RIE-1 cells, although at reduced potencies
when compared with Ha-RasVal-12 (49). We established RIE-1
cells stably expressing the parental and mutant Ha-RasVal-12
proteins and verified that each protein was expressed at com-
parable levels by Western blot analysis (data not shown). Each
mutant caused partial increases in cyclin D1 and Rb hyper-
phosphorylation that were less than the increases caused by
Ha-RasVal-12 (Figs. 7, A and B). These results, when taken
together with the inhibitor analyses described above, suggest
that Ras up-regulation of cyclin D1 expression is dependent on
the coordinate activation of Raf and PI3K pathways. Finally,
the ability of Ha-RasVal-12/Ser-35, but not activated Raf-22W, to
cause a limited up-regulation of cyclin D1 may be due to its
ability to bind to other Ras effectors, including AF-6 (10).
We also used transient expression analyses of cyclin D1
promoter reporter plasmids as a third approach to evaluate the
Ras signaling pathways important for up-regulation of cyclin
D1. Cyclin D1 promoter constructs containing either the wild
type sequence or with a point mutation in an AP-1 site were
used for these analyses (19). We found that the AP-1 site was
dispensable for Ras-mediated stimulation of the cyclin D1 ex-
pression in NIH 3T3 cells but was essential for Ras-mediated
stimulation in RIE-1 cells (Fig. 8). These results suggest that
Ras activation of AP-1, via a Raf-independent pathway, is
important for up-regulation of cyclin D1 expression in RIE-1
cells.
Up-regulation of p21 Is Associated with Ras Transformation
of Fibroblasts and Epithelial Cells—A number of studies sug-
FIG. 4. Ras and Raf differentially
regulated Rb hyperphosphorylation
and activation of E2F-responsive
gene expression. A, exponentially grow-
ing cells stably expressing each DNA
were harvested, and equal total protein
was analyzed by Western blotting to de-
tect changes in Rb phosphorylation. B,
Ras, but not Raf, causes up-regulation of
transcription from the E2F-responsive re-
porter plasmid in RIE-1 cells. NIH 3T3 or
RIE-1 cells were transiently transfected
with pAX142 expression vectors encoding
activated Ha-RasLeu-61 or Raf-22W, to-
gether with a reporter plasmid where the
luciferase gene is under control of the
mouse E2F1 (2176 to 136) promoter.
Whereas both Ras and Raf stimulated ex-
pression in NIH 3T3 cells, only Ras stim-
ulated expression in RIE-1 cells. Data
shown are representative of at least three
independent assays.
FIG. 5. Cyclin D1 alone or in combination with oncogenic Raf
is not sufficient for transformation of RIE-1 cells. A, 500 ng of
Raf-22W, cyclin D1 or K-RasVal-12 (or 500 ng of each for cooperation
assays) was transfected into RIE-1 cells, and the total number of foci
was scored after 21 days. The number of foci of transformed cells
represents the average of three dishes. Data shown are representative
of three independent experiments and are the average of triplicate
plates for each condition. B, exponentially growing RIE-1 cells stably
expressing Raf-22W and cyclin D1 were harvested, and total protein
concentrations were determined by BCA protein assay. The relative
levels of cyclin D1 protein and Raf-22W expression were determined by
a Western blot of equal amounts of total cellular lysates.
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gested that p21 antagonizes the ability of Ras or Raf to stim-
ulate cellular proliferation (12–14). However, since these stud-
ies evaluated the relationship between p21 expression and
transient Ras or Raf activation, the role of p21 has in the
maintenance of Ras-induced transformation remained unre-
solved. Additionally, we wanted to determine if Ras and Raf
regulated p21 expression similarly in NIH 3T3 and RIE-1 cells.
We used Western blot analyses to evaluate the p21 levels in
NIH 3T3 and RIE-1 cells stably expressing activated Ras or
Raf. Unexpectedly, we found that NIH(Ras), and to a lesser
degree NIH(Raf), cells showed greatly up-regulated levels of
p21 protein (Fig. 9A). This result contrasts with transient
expression studies that indicated that high p21 expression
antagonized Ras and Raf induction of cellular proliferation (27,
28). We also found that activated versions of all three Ras
proteins caused up-regulation of steady state p21 protein levels
in RIE-1 cells, whereas only a very limited increase was seen in
RIE(Raf) cells. These observations suggest that up-regulation,
rather than down-regulation, of p21 may contribute to Ras
transformation of NIH 3T3 and RIE-1 cells.
The limited elevation of p21 seen in RIE(Raf) cells suggested
that Ras requires activation of multiple effector pathways to
cause up-regulation of p21 expression. We found that treat-
ment with the U0126 or PD98059 MEK inhibitors completely
abolished p21 up-regulation in RIE(Ras) cells (Fig. 9B; data not
shown), suggesting a necessary role of the Raf/ERK pathway in
Ras regulation of p21. In contrast, the limited ability of treat-
ment with LY294002 to reduce p21 levels suggests a minor role
of the PI3K effector pathway in regulating p21 expression.
Consistent with these observations, we found that RIE-1 cells
stably expressing the Ha-RasVal-12/Ser-35 effector domain mu-
tant showed a greater increase in p21 than was seen in cells
expressing the Ha-RasVas-12/Cys-40 and Ha-RasVal-12/Gly-37 mu-
tants (Fig. 9C; and data not shown). Thus, Ras activation of Raf
is important for up-regulation of p21 in both NIH 3T3 and
RIE-1 cells. However, additional effector pathways are impor-
tant for Ras to up-regulate p21 in RIE-1 cells.
Ras Causes Opposing Changes in p27 Expression in NIH 3T3
and RIE-1 Cells—A clear understanding of Ras regulation of
p27 expression and the role of p27 in mediating Ras transfor-
mation have not been established. However, several lines of
evidence suggest that Ras down-regulation of p27 protein lev-
els, via activation of the Raf/ERK pathways, may contribute to
Ras stimulation of G1 progression (12–14). Since many of these
studies assessed the consequences of transient activation of
Ras, we compared the consequences of sustained Ras and Raf
activation on NIH 3T3 and RIE-1 cells on p27 protein levels.
As expected, p27 protein levels were low in subconfluent and
proliferating cultures of untransformed NIH 3T3 cells (Fig.
10A). Surprisingly, we found that p27 protein levels were
greatly elevated in both NIH(Raf) and NIH(Ras) cells, suggest-
ing that p27 up-regulation may facilitate both Ras and Raf
transformation of NIH 3T3 cells. In contrast, we found that p27
levels were high in untransformed RIE-1 cells, unchanged in
RIE(Raf) cells, and reduced in RIE(Ras) cells. Thus, Ras down-
regulation of p27 protein expression, via Raf-independent path-
ways, may contribute to Ras transformation of RIE-1 cells.
Since treatment of RIE(Ras) cells with either U0126 or
LY294002 did not restore p27 levels to that seen in control,
vector-transfected cells, it appears that Ras down-regulation of
p27 expression occurs via activation of Raf- and PI3K-inde-
pendent pathways (Fig. 10B).
DISCUSSION
A clear understanding of what Ras-regulated cell cycle
events cause growth transformation remains to be achieved, in
part, due to possible cell type differences and to different con-
sequences of transient versus sustained activation of Ras (12–
14). In the present study we have addressed cell type differ-
ences and compared the consequences of sustained Ras
activation in NIH 3T3 mouse fibroblasts and RIE-1 rat intes-
FIG. 6. Inhibition of ERK activation causes morphological re-
version of RIE(Ras) cells and decreases cyclin D1 levels. A, cells
stably expressing the K-RasVal-12 were seeded, allowed to adhere, and
each inhibitor or Me2SO control was added to the growth medium.
Concentrations of pharmacological inhibitors used were 10 mM for MEK
inhibitor (U0126) and 20 mM for the PI3K inhibitor (LY294002). Photos
were taken after 48-h treatments. B and C, RIE-1 cells treated with
vehicle or drugs were harvested, and total protein concentrations were
determined by BCA protein assay. The relative levels of cyclin D1
protein (B) and phospho-ERK (C) expression were determined by a
Western blot of equal total cellular lysates.
FIG. 7. Individual Ras effector mutants do not fully up-regu-
late cyclin D1 protein levels and Rb hyperphosphorylation.
Mass populations of RIE-1 cells stably expressing Ha-RasVal-12, or the
Ser-35, Gly-37, or Cys-40 effector domain mutants of Ha-RasVal-12, were
harvested, and equivalent amounts of total protein were analyzed by
Western blotting to detect cyclin D1 protein levels (A), Rb hyperphos-
phorylation (B), and cyclin E-associated kinase activity (C), by in vitro
kinase analyses using recombinant histone H1 as a substrate. IP,
immunoprecipitation.
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tinal epithelial cells. Ras causes transformation of NIH 3T3
cells by activation of either Raf-dependent or Raf-independent
pathways, whereas Raf-dependent pathways are necessary but
not sufficient to cause transformation of RIE-1 cells. Therefore,
we also assessed the contribution of Raf-dependent and Raf-
independent effector pathways in regulating the expression of
cyclin D1, p21, and p27. Several novel and unexpected conclu-
sions were reached. First, the up-regulation of p21 seen in
Ras-transformed NIH 3T3 and RIE-1 cells contrasts with pre-
vious transient expression analyses and instead supports a
positive role for p21 in mediating Ras transformation of NIH
3T3 and RIE-1 cells. Second, whereas up-regulation of p27 may
promote Ras transformation of NIH 3T3 cells, down-regulation
may promote Ras transformation of RIE-1 cells. Finally,
whereas Raf activation is sufficient to facilitate Ras regulation
of cyclin D1, p21, and p27 in NIH 3T3 cells, Raf-independent
pathways, including PI3K-dependent activity, are critical for
Ras regulation of these cell cycle components in RIE-1 cells.
When taken together, our observations emphasize the impor-
tance of cell type differences, and different consequences of
transient versus sustained Ras activation, in how Ras causes
deregulation of cell cycle progression.
We first assessed the ability of Ras to cause up-regulation of
cyclin D1 in NIH 3T3 and RIE-1 cells. In agreement with
previous reports (27, 28, 50), we found that activation of Raf
alone was sufficient to increase steady state levels of cyclin D1
protein levels in NIH 3T3 cells. In contrast, our analyses im-
plicated both Raf and PI3K as important effectors for Ras
up-regulation of cyclin D1 in RIE-1 cells. Transient expression
reporter analyses, as well as Northern blot analyses of stably
transfected cells, determined that Ras up-regulation of cyclin
D1 in RIE-1 cells occurred at the level of gene transcription.
Recent studies have implicated PI3K as an important regulator
of cyclin D1 protein expression, by promoting increased gene
transcription or by decreasing protein degradation (23, 24).
Finally, we found that forced overexpression of cyclin D1 in
Raf-expressing RIE-1 cells was not sufficient to allow Raf to
cause transformation of RIE-1 cells. Thus, Ras must cause
other changes, in addition to the up-regulation of cyclin D1
expression, to cause inactivation of Rb and to promote growth
transformation of RIE-1 cells.
We next evaluated the consequences of Ras transformation
on p21 expression in NIH 3T3 and RIE-1 cells. Although a
previous study found increased p21 levels in Ras-transformed
NIH 3T3 cells (37), the majority of studies suggested that p21
FIG. 8. AP1 site is important for
Ras-mediated stimulation of tran-
scription from the cyclin D1 pro-
moter in RIE-1 but not NIH 3T3 cells.
RIE-1 cells were transiently transfected
with the wild type (wt) cyclin D1-Lucifer-
ase reporter plasmid or the 2963 pro-
moter with a point mutation in the AP1
site and activating constructs consisting
of pAX142 empty vector or pAX142 encod-
ing Ha-RasLeu-61. DNA was transfected
via incubation with cationic lipids for 24 h
followed by incubation in complete me-
dium for 24 h and a subsequent starva-
tion for 12–16 h. Luciferase activity was
determined and converted to fold activa-
tion relative to the activity detected with
the empty vector transfected control.
FIG. 9. Oncogenic Ras-mediated up-regulation of p21 is Raf-
dependent. A, exponentially growing cells stably expressing the indi-
cated constructs were harvested, and equal total protein was analyzed
by Western blotting to detect changes in p21 levels. B, concentrations of
pharmacological inhibitors used were 10 mM for MEK inhibitor (U0126)
and 20 mM for the PI3K inhibitor (LY294002). C, exponentially growing
cells stably expressing either pDCR Ha-RasVal-12, Ha-RasVal-12/Cys-40, or
Ha-RasVal-12/Ser-35 were harvested, and equal total protein was analyzed
by Western blotting to detect changes in p21.
FIG. 10. Activation of the Raf/ERK pathway does not down-
regulate p27 expression. A, exponentially growing cells stably ex-
pressing each DNA were harvested, and equal total protein was ana-
lyzed by Western blot analyses to detect changes in p21 or p27 levels. B,
RIE-1 cells stably expressing K-RasVal-12 were seeded and allowed to
adhere, and each inhibitor or Me2SO control was added to the growth
medium. Concentrations of inhibitors used were 10 mM for MEK inhib-
itor (U0126) and 20 mM for the PI3K inhibitor (LY294002).
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expression antagonized the proliferative activity of Ras (12–
14). Therefore, we were surprised to find that the steady state
levels of p21 were up-regulated in both Ras-transformed NIH
3T3 and RIE-1 cells. These opposing observations may reflect
the different consequences of transient versus stable and sus-
tained Ras activity. Since our goal was to determine how p21
may support the transformed growth state caused by sustained
Ras activation, our results argue that up-regulation of p21 may
facilitate the inactivation of Rb to promote Ras transformation.
The stoichiometry of p21 and other components can influence
whether p21 serves a negative or positive regulatory role in G1
progression. The up-regulation of p21 seen in Ras-transformed
NIH 3T3 and RIE-1 cells may serve a positive regulatory role
and facilitate activation of cyclin D1-CDK complexes. Such a
role has been observed in other studies where p21 is found
complexed with active cyclin D-CDK complexes (38, 51–53). In
contrast to our observations, it was found that the loss of p21
function allowed Ras to cause transformation of mouse kerati-
nocytes (30). Therefore, p21 may exhibit cell type distinct roles
in either facilitating or antagonizing Ras transformation.
The significant up-regulation of p21 in NIH(Raf) cells sug-
gests that Ras causes up-regulation of p21 primarily by acti-
vation of Raf in NIH 3T3 cells. This is consistent with previous
studies that showed that Raf activation alone can cause p21
up-regulation in fibroblasts. In contrast, RIE(Raf) cells showed
only limited up-regulation of p21 levels. Treatment of RIE(Ras)
cells with LY294002 caused a modest reduction in p21,
whereas U0126 treatment reduced the level of p21 to that seen
in untransformed RIE-1 cells. Thus, Ras activation of Raf is
necessary, but not sufficient, to cause up-regulation of p21.
Instead, the coordinate activation Raf and PI3K (and other)
effector pathways may be required for Ras up-regulation of p21
protein expression in RIE-1 cells. Finally, it remains possible
that the up-regulation of p21 in Ras-transformed cells may not
be a direct consequence of Ras activation and, instead, may
reflect a compensatory response of cells to Ras-induced growth
transformation.
We also evaluated the consequences of Ras transformation
on a second cell cycle inhibitor p27. Although p27 expression is
correlated strongly with growth inhibition, a clear relationship
between Ras transformation and p27 expression has not been
established. Ras transformation of some cell lines resulted in
down-regulation of p27 expression (e.g. Rat 6 fibroblasts,
CCL39 hamster fibroblasts, and IEC-6 rat intestinal epithelial
cells) but no change in others (NIH 3T3 cells) (37). In our
analyses we found that p27 protein levels were stably up-
regulated in Ras-transformed NIH 3T3 cells but down-regu-
lated in Ras-transformed RIE-1 cells. The opposing conse-
quences of sustained Ras activity on p27 expression suggest
different roles of p27 in Ras transformation of these two cell
types. The increased expression of p27 in NIH(Ras) cells sug-
gests that p27 may serve a positive regulatory role, perhaps by
promoting the assembly and nuclear translocation of active
cyclin D1-CDK complexes (38, 54, 55). In contrast, a reduction
of p27 function appears to be important for Ras transformation
of RIE-1 cells. The down-regulation of p27 in intestinal epithe-
lial cell transformation is consistent with the decreased levels
of p27 seen in a variety of epithelial cell-derived human cancers
(16). p27 can act as an inhibitor of cyclin E-dependent kinase
activity. Consistent with this role, we found that both cyclin D-
and cyclin E-dependent kinase activities were increased in
Ras-transformed RIE-1 cells.
p27 protein levels were elevated in both Ras- and Raf-trans-
formed NIH 3T3 cells, suggesting that Ras up-regulation of p27
in fibroblasts is mediated primarily through the Raf effector
signaling pathway (21, 27, 28). However, how Ras causes down-
regulation of p27 levels in RIE-1 cells is not clear. RIE(Raf)
cells showed levels of p27 that were similar to the high levels
seen in untransformed RIE-1 cells, and neither U0126 nor
LY294002 treatment of RIE(Ras) cells was able to restore p27
protein levels to that seen in untransformed RIE-1 cells. Thus,
this decrease in p27 levels does not appear to be due to Ras
activation of Raf or PI3K. Other possible mechanisms for Ras-
mediated down-regulation of p27 may involve an increase in
activation of cyclin E-CDK2 complexes, which have been shown
to phosphorylate p27 and initiate its targeting for degradation.
RhoA has also been implicated in plate-derived growth factor-
induced p27 degradation through regulation of cyclin E/CDK2
(56, 57). Thus, like cyclin D1 and p21, Ras regulation of p27
expression is mediated by distinct signaling pathways in NIH
3T3 and RIE-1 cells.
In summary, we have found that Raf-dependent and Raf-
FIG. 11. Ras regulation of cyclin D1, p21, and p27 by distinct signaling pathways in NIH 3T3 and RIE-1 cells. A, NIH 3T3 cells stably
expressing activated Ras and Raf show increased steady state levels of cyclin D1 (Cyc D1), p21, and p27. Consistent with previous observations,
we found that Ras activation of the Raf/ERK pathways alone was sufficient to regulate the expression of cyclin D1, p21, and p27. However, in
contrast to other studies, we found that sustained up-regulation of p21 and p27 was associated with Ras transformation of NIH 3T3 cells. B, RIE-1
cells stably expressing activated Ras showed increased steady state levels of cyclin D1 and p21, but down-regulation of p27, protein levels. RIE-1
cells stably expressing activated Raf showed a limited increase in steady state levels of p21 protein but no change in cyclin D1 or p27 protein levels.
However, since U0126 inhibition of ERKs reduced cyclin D1 and p21 protein levels in Ras-transformed RIE-1 cells, the Raf/ERK pathway is
necessary, but not sufficient, to regulate cyclin D1 and p21 expression. The partial down-regulation of cyclin D1 and p21 seen when Ras-
transformed RIE-1 cells are treated with LY294002 supports a role for the PI3K effector pathway in cyclin D1 and p21 regulation. Finally, since
neither U0126 nor LY294002 treatment restored p27 expression levels in Ras-transformed RIE-1 cells, Ras must down-regulate p27 expression by
Raf- and PI3K-independent effector pathways.
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independent signaling have distinct contributions to Ras reg-
ulation of cyclin D1, p21, and p27 expression in NIH 3T3 versus
RIE-1 cells (Fig. 11). Furthermore, p27 may have opposing
roles in the promotion of cell cycle progression in NIH 3T3 and
RIE-1 cells. Our observations also emphasize that transient
and sustained Ras activation may have different consequences
on the expression and function of cell cycle inhibitors. An im-
portant strength of transient expression analyses is the ability
to make functional connections between Ras activation and
specific components of cell cycle regulation. In contrast, the
importance of defining the consequences due to sustained Ras
activation is that this determines the changes that may be
involved in maintenance of the transformed state. These
changes will reflect the net consequences of Ras activation,
together with subsequent actions in response to these changes,
and finally, changes that occur in response to altered cell
growth. Thus, our analyses of the consequences of sustained
Ras activation in RIE-1 cells may provide a more accurate view
of what changes in cell cycle regulation are important for ab-
errant Ras transformation of human carcinoma cells, and
hence, how specific cell cycle regulators may be targeted for
cancer treatment.
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